These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21703321)

  • 1. The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model.
    Hontelez JA; Nagelkerke N; Bärnighausen T; Bakker R; Tanser F; Newell ML; Lurie MN; Baltussen R; de Vlas SJ
    Vaccine; 2011 Aug; 29(36):6100-6. PubMed ID: 21703321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results.
    Andersson KM; Paltiel AD; Owens DK
    Vaccine; 2011 Aug; 29(36):6107-12. PubMed ID: 21736912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
    Andersson KM; Stover J
    Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of a modestly effective HIV vaccine in the United States.
    Long EF; Owens DK
    Vaccine; 2011 Aug; 29(36):6113-24. PubMed ID: 21510996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: a modeling study.
    Nagelkerke NJ; Hontelez JA; de Vlas SJ
    Vaccine; 2011 Aug; 29(36):6079-85. PubMed ID: 21718745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.
    Selinger C; Bershteyn A; Dimitrov DT; Adamson BJS; Revill P; Hallett TB; Phillips AN; Bekker LG; Rees H; Gray G
    Vaccine; 2019 Apr; 37(16):2258-2267. PubMed ID: 30890385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expected epidemiological impacts of introducing an HIV vaccine in Thailand: a model-based analysis.
    Schneider K; Kerr CC; Hoare A; Wilson DP
    Vaccine; 2011 Aug; 29(36):6086-91. PubMed ID: 21723902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia.
    Gray RT; Ghaus MH; Hoare A; Wilson DP
    Vaccine; 2011 Aug; 29(36):6125-9. PubMed ID: 21703320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projected economic evaluation of the national implementation of a hypothetical HIV vaccination program among adolescents in South Africa, 2012.
    Moodley N; Gray G; Bertram M
    BMC Public Health; 2016 Apr; 16():330. PubMed ID: 27079900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
    Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
    Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.
    de Montigny S; Adamson BJS; Mâsse BR; Garrison LP; Kublin JG; Gilbert PB; Dimitrov DT
    Sci Rep; 2018 Apr; 8(1):6066. PubMed ID: 29666455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How low can you go: the impact of a modestly effective HIV vaccine compared with male circumcision.
    Kaldor JM; Wilson DP
    AIDS; 2010 Oct; 24(16):2573-8. PubMed ID: 20829677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
    Rerks-Ngarm S; Pitisuttithum P; Excler JL; Nitayaphan S; Kaewkungwal J; Premsri N; Kunasol P; Karasavvas N; Schuetz A; Ngauy V; Sinangil F; Dawson P; deCamp AC; Phogat S; Garunathan S; Tartaglia J; DiazGranados C; Ratto-Kim S; Pegu P; Eller M; Karnasuta C; Montefiori DC; Sawant S; Vandergrift N; Wills S; Tomaras GD; Robb ML; Michael NL; Kim JH; Vasan S; O'Connell RJ;
    J Infect Dis; 2017 Apr; 215(8):1255-1263. PubMed ID: 28329190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential future impact of a partially effective HIV vaccine in a southern African setting.
    Phillips AN; Cambiano V; Nakagawa F; Ford D; Lundgren JD; Roset-Bahmanyar E; Roman F; Van Effelterre T
    PLoS One; 2014; 9(9):e107214. PubMed ID: 25207973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the impact of RV144-like vaccines on HIV transmission.
    Hankins CA; Glasser JW; Chen RT
    Vaccine; 2011 Aug; 29(36):6069-71. PubMed ID: 21762753
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.
    Herbeck JT; Peebles K; Edlefsen PT; Rolland M; Murphy JT; Gottlieb GS; Abernethy N; Mullins JI; Mittler JE; Goodreau SM
    Vaccine; 2018 Jan; 36(4):514-520. PubMed ID: 29241646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa.
    Amirfar S; Hollenberg JP; Abdool Karim SS
    J Acquir Immune Defic Syndr; 2006 Oct; 43(2):219-25. PubMed ID: 16951648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
    Tan N; Sharma M; Winer R; Galloway D; Rees H; Barnabas RV
    Vaccine; 2018 Aug; 36(32 Pt A):4830-4836. PubMed ID: 29891348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of a partially effective HIV vaccine: assessing limitations at the population level.
    Selinger C; Dimitrov DT; Welkhoff PA; Bershteyn A
    Int J Public Health; 2019 Jul; 64(6):957-964. PubMed ID: 30982082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.